Blood transfusion · adults with kidney failure treated with long‐term HD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with cancer with venous thromboembolism
Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).
1 finding from 1 review
Recurrent VTE · patients with cancer with venous thromboembolism
Low molecular weight heparin showed no clear difference in recurrent VTE compared with unfractionated heparin (low certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Additional side effects of heparin · children with congenital heart disease undergoing CC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Heparin‐induced thrombocytopenia (HIT) · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower heparin‐induced thrombocytopenia (HIT) (low certainty).
1 finding from 1 review
Major bleeding · CRRT
Citrate probably leads to lower major bleeding compared with unfractionated heparin (moderate certainty).
1 finding from 1 review
Death at 28 days · CRRT
Citrate showed no clear difference in death at 28 days compared with unfractionated heparin (moderate certainty).
1 finding from 1 review
Successful prevention of clotting · CRRT
Citrate probably leads to higher successful prevention of clotting compared with unfractionated heparin (moderate certainty).
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
1 finding from 1 review
Recovery of kidney function · CRRT
Citrate showed no clear difference in recovery of kidney function compared with unfractionated heparin (low certainty).
1 finding from 1 review
Thrombocytopenia · CRRT
Citrate showed no clear difference in thrombocytopenia compared with unfractionated heparin (low certainty).
1 finding from 1 review
Cost to health care services · CRRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Arterial thrombotic events (6 to 48 hours after CC) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in arterial thrombotic events (6 to 48 hours after CC) (moderate certainty).
1 finding from 1 review
Intervention not reported
Major bleeding events (timing not specified) · children with congenital heart disease undergoing CC
The intervention showed no clear difference in major bleeding events (timing not specified) (moderate certainty).
1 finding from 1 review